We have focused on genomic abnormalities in angioimmunoblastic T-cell lymphoma (AITL). Furthermore, we are continuing research to utilize the findings of these genomic abnormalities in diagnosis and treatment of AITL. Hopefully, this research will lead to improved management of AITL patients in the near future.